Please login to the form below
CNS
This page shows the latest CNS news and features for those working in and with pharma, biotech and healthcare.
Shionogi makes buyout play for Tetra ahead of Alzheimer’s readout
This new collaboration with Tetra reinforces our steadfast commitment to advancing cutting-edge science in central nervous system (CNS) disorders including Alzheimer’s disease,” he added.
Latest news
-
Nektar’s opioid analgesic slammed with FDA panel rejection
According to Nektar, NKTR-181 provides the same levels of pain relief as standard opioid products, but with reduced central nervous system (CNS) side-effects, namely euphoria.
-
Intra-Cellular soars on FDA approval of schizophrenia drug
According to Matteis, the Caplyta approval indicates that regulators will “often look at a mixed efficacy package in CNS through a 'glass half full lens'," due to the increased need for
-
FDA clears SK Life Science’s anti-epileptic drug Xcopri
Today’s approval is a major step toward our goal of becoming a fully-integrated global pharmaceutical company that can discover, develop and deliver new treatment options in epilepsy and CNS,”
-
Alkermes boosts CNS presence with $950m Rodin acquisition
The deal will see Alkermes expand its reach into central nervous system (CNS) diseases, by gaining a portfolio of pre-clinical assets for Alzheimer’s disease, Huntington’s disease, frontotemporal dementia ... to us as we have advanced our internal
-
Karuna’s shares spike on schizophrenia drug data
CNS but prevents unwanted side effects on peripheral nerves.
More from news
Approximately 5 fully matching, plus 178 partially matching documents found.
Latest Intelligence
-
Rethinking trials: the pros and cons of protocol amendments
We typically see more amendments in oncology and CNS. We also see a higher incidence and average number of amendments in later stage phase 2 and 3 studies.
-
China’s clinical trial shake-up
These reporting rules require sponsors to upload information such as endpoints and eligibility criteria to www.chinadrugtrials.org.cn.
-
Key considerations for disease- modifying Parkinson’s disease trials
By Dr Peter Schueler, Senior Vice President, Drug Development Services and Haichen Yang, Vice President, Global Therapeutic Lead, both at CNS, ICON plc.
-
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe
The company is working on RNAi molecules which can work in CNS, something which would expand its therapeutic possibilities enormously, and hopes to have its first CNS-targetting candidate enter clinical
-
A quest for innovative solutions
PRISM has matured into an artery of new opportunities such as its collaboration on RADAR-CNS (Remote Assessment of Disease and Relapse - Central Nervous System), an initiative that aims to develop
More from intelligence
Approximately 0 fully matching, plus 42 partially matching documents found.
Latest appointments
-
New hires at FibroGen, Saniona and Turbine
He is a veteran biotech leader, with over 23 years of experience in rare diseases and CNS.
-
Axovant poaches Allergan’s and Teva’s chief medical and science officers
development. “We have a wonderful opportunity to develop life-changing medicines for patients with CNS diseases.
-
Damien McDevitt moves from GSK to Acadia Pharmaceuticals
At Acadia, which focuses on the development and commercialisation of medicines for central nervous system (CNS) disorders, McDevitt will report to the company’s president and chief executive officer Steve Davis. ... This expertise, combined with his
-
Ron Menezes joins Almirall’s Aqua Pharmaceuticals
Menezes joins the group from Depomed Pharmaceuticals, where he served as vice president of sales and sales operations, pain and CNS.
-
emotive boosts its client services team
Joining as a senior account director, Andy Parry has 9 years’ experience in healthcare communications and has worked on global brands in CNS, infectious diseases, respiratory and rare disease.
More from appointments
Approximately 0 fully matching, plus 26 partially matching documents found.
Latest from PMHub
-
New recommendations to stimulate braver and bolder communications
Lilianna Husseini, Director Communications, Oncology, Pfizer Global. Heidi LaPensée, Brand Lead, CNS, Sanofi UK.
-
Diagnosing the lag in neuropsychiatric treatments
Unlike the other organs in our body, the central nervous system (CNS) is surrounded by the Blood Brain Barrier (BBB). ... To say the BBB presents a formidable challenge in CNS drug development is an understatement.
-
Innovative approaches in the treatment of multiple sclerosis
Multiple Sclerosis (MS) is a chronic autoimmune disease that affects the central nervous system (CNS), leading to progressive and permanent disability. ... In the central nervous system (CNS, which includes the brain, optic nerves and spinal cord),
-
Innovative approaches in the treatment of multiple sclerosis
Multiple Sclerosis (MS) is a chronic autoimmune disease that affects the central nervous system (CNS), leading to progressive and permanent disability. ... In the central nervous system (CNS, which includes the brain, optic nerves and spinal cord),
-
Shionogi Ltd. appoints Star for UK launch
Their pipeline focuses on infectious disease, pain, CNS and oncology. Star were chosen as preferred partner on the basis of the company’s ability to provide the very best talent to
More from PMHub
Approximately 0 fully matching, plus 11 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Regeneron says antibody for COVID-19 could be ready this year
- Amgen adds Otezla to the COVID-19 candidate list
- UK clears NHS use of Gilead’s remdesivir for COVID-19 patients
- EMA clears BMS’ oral multiple sclerosis drug Zeposia
- NICE approves Roche’s Tecentriq in TNBC after revising deal
- CEPI-backed coronavirus vaccine from Novavax starts trials
- IFPMA industry association conference: ‘no-one left behind’ on coronavirus vaccine
- Roche/Gilead tag team fights COVID-19 with Actemra/remdesivir
- GSK plans to produces one billion doses of vaccine adjuvant for COVID-19
- The big issue
- The field team are off the road! What should they do next?
- INFOGRAPHIC 02: The Importance of clinical study websites
PMHub
Wilmington Healthcare
A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...
Latest intelligence
- The big issue
- Whether you want to lead or follow, you need to understand the elephant in the C-suite...
- INFOGRAPHIC 02: The Importance of clinical study websites
- Here’s a infographic of why clinical study websites are important to patient recruitment and retention strategies…...
- Working with, Advocating for, and Empowering Patients
- A holistic view of how to work with patients virtually...
Quick links
Infographics
